What is Citius Oncology, Inc.'s forfeited or expired (in shares)?

Citius Oncology, Inc. (CTOR) reported forfeited or expired (in shares) of $2.02 in Q3 2025.

What does forfeited or expired (in shares) mean?

The average exercise price associated with stock options that were forfeited or expired during the reporting period. This metric assists in evaluating the historical pricing of equity compensation relative to the company's stock performance.

Citius Oncology, Inc. CTOR Forfeited or expired (in shares)

Forfeited or expired (in shares) at other companies

VestisVSTS

$18.60-5.0%

WhirlpoolWHR

$179.93+17.4%

Option Care Health, Inc.OPCH

$26.32—

Ivanhoe ElectricIE

$12.61+43.8%

KemperKMPR

$71.03+1.6%

Willdan GroupWLDN

$26.26+37.8%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s forfeited or expired (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s forfeited or expired (in shares)?: Citius Oncology, Inc. (CTOR) reported forfeited or expired (in shares) of $2.02 in Q3 2025.
What does forfeited or expired (in shares) mean?: The average exercise price associated with stock options that were forfeited or expired during the reporting period. This metric assists in evaluating the historical pricing of equity compensation relative to the company's stock performance.